Compare Neurocrine Biosciences Inc (NBIX) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while YieldMax TSLA Option Income Strategy ETF trades at $25.63. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | TSLY | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $180.55 | $48.25 |
52-Week Low | $123.10 | $25.07 |
Enterprise Value | $16.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
TSLY, the YieldMax TSLA Option Income Strategy ETF, trades at $25.07, down 2.57% today amid a bearish technical signal. The ETF generates high income through weekly distributions, with recent dividends ranging from $0.26 to $0.52 per share, but faces criticism for capping upside during Tesla rallies. Its strategy relies on synthetic Tesla exposure and covered call overlays, producing an annualized yield near 52.65%, though distributions are largely return of capital.
The outlook is cautious due to structural limitations that sacrifice capital appreciation for income, with risks including volatility from Tesla's performance and option strategy complexity. Investors prioritizing yield may find value, but those seeking growth could underperform Tesla's equity returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
